Inhaled corticosteroids in COPD: Personalising the therapeutic choice

There has been a recent surge in interest in the role of inhaled corticosteroids (ICS) in the treatment of COPD, especially regarding patients with high eosinophil counts. Evidence has shown that despite the increase in localised adverse effects and a small increase in non-fatal pneumonia events wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaw, J A, Irusen, E M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: South African Medical Association 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432921/
https://www.ncbi.nlm.nih.gov/pubmed/34541493
http://dx.doi.org/10.7196/AJTCCM.2018.v24i1.184
_version_ 1783751267865067520
author Shaw, J A
Irusen, E M
author_facet Shaw, J A
Irusen, E M
author_sort Shaw, J A
collection PubMed
description There has been a recent surge in interest in the role of inhaled corticosteroids (ICS) in the treatment of COPD, especially regarding patients with high eosinophil counts. Evidence has shown that despite the increase in localised adverse effects and a small increase in non-fatal pneumonia events with ICS use, ICS still have an important role to play in reducing exacerbation rates and addressing the inflammation that is at the heart of the pathogenesis of COPD. Current international guidelines recommend the use of ICS only in patients with severe disease. This review examines the potential role of ICS in all COPD patients.
format Online
Article
Text
id pubmed-8432921
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher South African Medical Association
record_format MEDLINE/PubMed
spelling pubmed-84329212021-09-16 Inhaled corticosteroids in COPD: Personalising the therapeutic choice Shaw, J A Irusen, E M Afr J Thorac Crit Care Med Review There has been a recent surge in interest in the role of inhaled corticosteroids (ICS) in the treatment of COPD, especially regarding patients with high eosinophil counts. Evidence has shown that despite the increase in localised adverse effects and a small increase in non-fatal pneumonia events with ICS use, ICS still have an important role to play in reducing exacerbation rates and addressing the inflammation that is at the heart of the pathogenesis of COPD. Current international guidelines recommend the use of ICS only in patients with severe disease. This review examines the potential role of ICS in all COPD patients. South African Medical Association 2018-04-03 /pmc/articles/PMC8432921/ /pubmed/34541493 http://dx.doi.org/10.7196/AJTCCM.2018.v24i1.184 Text en https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution - NonCommercial Works License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Shaw, J A
Irusen, E M
Inhaled corticosteroids in COPD: Personalising the therapeutic choice
title Inhaled corticosteroids in COPD: Personalising the therapeutic choice
title_full Inhaled corticosteroids in COPD: Personalising the therapeutic choice
title_fullStr Inhaled corticosteroids in COPD: Personalising the therapeutic choice
title_full_unstemmed Inhaled corticosteroids in COPD: Personalising the therapeutic choice
title_short Inhaled corticosteroids in COPD: Personalising the therapeutic choice
title_sort inhaled corticosteroids in copd: personalising the therapeutic choice
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432921/
https://www.ncbi.nlm.nih.gov/pubmed/34541493
http://dx.doi.org/10.7196/AJTCCM.2018.v24i1.184
work_keys_str_mv AT shawja inhaledcorticosteroidsincopdpersonalisingthetherapeuticchoice
AT irusenem inhaledcorticosteroidsincopdpersonalisingthetherapeuticchoice

Ejemplares similares